Envonalkib is a pharmaceutical drug for cancer treatment. It belongs to the class of anaplastic lymphoma kinase inhibitors (ALK inhibitors).
In China, it is approved for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received treatment with ALK inhibitors.